Plasmid News and Research

RSS

Adamis acquires cancer vaccine technology from UCSD

Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.

20 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

IncP-1 plasmids can transport antibiotic resistance genes between bacterial species

The part of bacterial DNA that often carries antibiotic resistance is a master at moving between different types of bacteria and adapting to widely differing bacterial species, shows a study made by a research team at the University of Gothenburg in cooperation with Chalmers University of Technology. The results are published in an article in the scientific journal Nature Communications.

12 Apr 2011

Researchers manage to grow human rhinovirus in culture using sinus tissue

Using sinus tissue removed during surgery at University of Wisconsin Hospital and Clinics, researchers at the University of Wisconsin-Madison have managed to grow a recently discovered species of human rhinovirus, the most frequent cause of the common cold, in culture.

11 Apr 2011

New nonviral method to create cardiac cells

Johns Hopkins scientists have developed a simplified, cheaper, all-purpose method they say can be used by scientists around the globe to more safely turn blood cells into heart cells. The method is virus-free and produces heart cells that beat with nearly 100 percent efficiency, they claim.

11 Apr 2011

Scarab Genomics, CellMed enter agreement for Clean Genome E. coli Technology

Scarab Genomics announced a strategic agreement today with CellMed AG, a BTG International group company, in which CellMed AG will use Scarab Genomics' Clean Genome E. coli Technology in a new product development in the life science field.

7 Apr 2011

Plasmid containing Sindbis replicase genes can destruct lung cancer

Alpha viruses, such as Sindbis virus, carry their genetic information on a single strand of RNA. On infection they use a protein, replicase, to produce double stranded RNA which is used as genetic material to make more viruses. However the body recognizes dsRNA as foreign, and infected cells initiate an immune response.

28 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine.

3 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

Vical 2010 net loss increases to $30.4 million

Vical Incorporated today reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010.

10 Feb 2011

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines.

7 Feb 2011

Novel AAV gene therapy offers various advantages

A new, simplified method for producing large amounts of viral vector cassettes capable of shuttling genes into host cells will help advance the promising field of gene therapy as applications move into large animal studies and human clinical trials.

6 Jan 2011

Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV

Profectus BioSciences, a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, and the AIDS Clinical Trials Group announced today the initiation of a phase 1 study of Profectus' multi-antigen HIV plasmid DNA vaccine administered with various doses of GENEVAX™ interleukin-12 pDNA adjuvant and delivered using the electroporation based TriGrid™delivery system developed by Ichor Medical Systems.

6 Jan 2011

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Profectus Biosciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that its GENEVAX™ IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I clinical study of an experimental DNA vaccine for the prevention of HIV infection.

15 Dec 2010

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.

13 Dec 2010

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.

9 Dec 2010

Roche introduces X-tremeGENE 9, X-tremeGENE HP reagents

Roche announced today the introduction of two new high-performance DNA transfection reagents for its innovative cellular analysis portfolio for life science research.

7 Dec 2010

New theoretical model could develop novel clinical decision making in cancer research

Schonfeld, a University of Illinois at Chicago professor of electrical and computer engineering, is studying gene expression and interactions in ways that are analogous to the workings of electrical or computer networks. He is project director and principal investigator of a four-year, $1.2 million National Institutes of Health grant.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010